Cite
HARVARD Citation
Myrehaug, S. et al. (n.d.). 92: [177Lu]Lu-Dota-Tate as First-Line Therapy for Patients with Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS): The NETTER-2 Study. Radiotherapy and oncology. pp. S40-S41. [Online].